Page last updated: 2024-10-30

lansoprazole and Colitis

lansoprazole has been researched along with Colitis in 12 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.

Research Excerpts

ExcerptRelevanceReference
"A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease."7.73Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005)
"To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days."7.73Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005)
"To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days."7.73Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006)
"A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole."7.71Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002)
"We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks."7.70[lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000)
"Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease."5.32Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003)
"Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events."5.31Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002)
"A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease."3.73Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005)
"To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days."3.73Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005)
"To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days."3.73Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006)
"A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole."3.71Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002)
"We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks."3.70[lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000)
"Colitis was induced with less C."1.48Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria. ( Adachi, S; Azuma, T; Fukuda, S; Hoshi, N; Inoue, J; Ishida, T; Kong, L; Ku, Y; Ooi, M; Otsuka, T; Tsukimi, T; Watanabe, D; Yamairi, H; Yasutomi, E; Yoshida, M, 2018)
"Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease."1.32Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003)
"Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events."1.31Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's2 (16.67)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Páramo-Zunzunegui, J1
Ortega-Fernandez, I1
Benito-Barbero, S1
Rubio-López, L1
Gandhi, T1
Sharma, A1
Vyas, N1
Gupta, P1
Parikh, M1
Shah, H1
Yasutomi, E1
Hoshi, N1
Adachi, S1
Otsuka, T1
Kong, L1
Ku, Y1
Yamairi, H1
Inoue, J2
Ishida, T1
Watanabe, D1
Ooi, M1
Yoshida, M1
Tsukimi, T1
Fukuda, S1
Azuma, T1
Bardet, R1
Moreno, JP1
Rodriguez, T1
Trémeau, AL1
Hernandez, É1
Bolot, AL1
Thomson, RD1
Lestina, LS1
Bensen, SP1
Toor, A1
Maheshwari, Y1
Ratcliffe, NR1
Mukherjee, S1
Rammer, M1
Kirchgatterer, A1
Höbling, W1
Knoflach, P1
Nakamura, M2
Asada, M2
Atsuda, K1
Matsui, H2
Watanabe, T1
Higuchi, K1
Arakawa, T1
Hibi, N2
Tsuchimoto, K2
Oda, M1
Ghilain, JM1
Schapira, M1
Maisin, JM1
De Maeght, S1
Piron, A1
Gerard, R1
Henrion, J1
Wilcox, GM1
Mattia, A1
Macaigne, G1
Boivin, JF1
Simon, P1
Chayette, C1
Cheaib, S1
Deplus, R1

Other Studies

12 other studies available for lansoprazole and Colitis

ArticleYear
Eosinophilic colitis: an infrequent disease with difficult diagnose.
    BMJ case reports, 2020, Sep-21, Volume: 13, Issue:9

    Topics: Aged, 80 and over; Biopsy; Colitis; Colon; Colonoscopy; Cromolyn Sodium; Drug Therapy, Combination;

2020
Lansoprazole a Proton Pump Inhibitor Prevents IBD by Reduction of Oxidative Stress and NO Levels in the Rat.
    Drug research, 2021, Volume: 71, Issue:7

    Topics: Animals; Colitis; Colon; Female; Inflammatory Bowel Diseases; Lansoprazole; Nitric Oxide; Oxidative

2021
Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:4

    Topics: Animals; Citrobacter rodentium; Colitis; Disease Models, Animal; Enterobacteriaceae Infections; Lans

2018
[A resistant diarrhea].
    Presse medicale (Paris, France : 1983), 2016, Volume: 45, Issue:3

    Topics: Aged, 80 and over; Anti-Ulcer Agents; Antidepressive Agents; Antidiarrheals; Colitis; Comorbidity; D

2016
Lansoprazole-associated microscopic colitis: a case series.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Co

2002
Diarrhea associated with lansoprazole.
    Journal of gastroenterology and hepatology, 2003, Volume: 18, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin

2003
Lansoprazole-associated collagenous colitis: a case report.
    Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen

2005
Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.
    Inflammopharmacology, 2005, Volume: 13, Issue:1-3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Infective Agents; Apoptosis; Autoradiography;

2005
Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites.
    Clinical hemorheology and microcirculation, 2006, Volume: 34, Issue:1-2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Binding Sites; Capillary Permeability; Colitis; Cy

2006
[lymphocytic colitis associated with lansoprazole treatment].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mu

2000
Collagenous colitis associated with lansoprazole.
    Journal of clinical gastroenterology, 2002, Volume: 34, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Collagen; Female; Humans; Lanso

2002
[Lansoprazole-associated collagenous colitis].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux;

2001